Clinical Trial Update: NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) [Phase 2]

View source ↗

Summary

This entry reports completion of a Phase 2 trial (KINECT) evaluating NBI-98854 for tardive dyskinesia in individuals with schizophrenia or schizoaffective disor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tardive Dyskinesia

Drugs mentioned

• NBI-98854

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Tardive Dyskinesia | Phase 2 | Status: COMPLETED | Results posted: 2017-11-08